Joseph L. Kuti, PharmD

Quick facts

Marketed products

• Imipenem, Cilastatin and Relebactam · Infectious Disease
  Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, cilastatin protects imipenem from renal degradation, and relebactam is a beta-lactamase inhibitor that prevents bacterial resistance.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Joseph L. Kuti, PharmD portfolio CI brief
• Joseph L. Kuti, PharmD pipeline updates RSS